{"id":"fosmidomycin-and-clindamycin-co-administration","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL203125","moleculeType":"Small molecule","molecularWeight":"183.10"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Fosmidomycin targets the DXR enzyme, which is crucial for the production of isoprenoids, a class of molecules involved in various cellular processes. By inhibiting DXR, fosmidomycin disrupts the isoprenoid biosynthesis pathway. Clindamycin, on the other hand, works by binding to the 50S ribosomal subunit, which prevents the elongation of the polypeptide chain during protein synthesis.","oneSentence":"Fosmidomycin inhibits the enzyme 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), which is involved in the biosynthesis of isoprenoids, while clindamycin inhibits protein synthesis by binding to the 50S ribosomal subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:49.935Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of malaria caused by Plasmodium falciparum"},{"name":"Treatment of bacterial infections, including those caused by Streptococcus and Staphylococcus species"}]},"trialDetails":[{"nctId":"NCT01464138","phase":"PHASE2","title":"Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated P.Falciparum Malaria in Children","status":"COMPLETED","sponsor":"Jomaa Pharma GmbH","startDate":"2010-09","conditions":"Malaria","enrollment":52},{"nctId":"NCT01361269","phase":"PHASE2","title":"Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria","status":"UNKNOWN","sponsor":"Zentopharm GmbH","startDate":"2011-06","conditions":"Malaria","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Fosmidomycin and Clindamycin co-administration","genericName":"Fosmidomycin and Clindamycin co-administration","companyName":"Jomaa Pharma GmbH","companyId":"jomaa-pharma-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fosmidomycin inhibits the enzyme 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), which is involved in the biosynthesis of isoprenoids, while clindamycin inhibits protein synthesis by binding to the 50S ribosomal subunit. Used for Treatment of malaria caused by Plasmodium falciparum, Treatment of bacterial infections, including those caused by Streptococcus and Staphylococcus species.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}